Symptomatic Heart Failure in Acute Leukemia Patients Treated With Anthracyclines

Yu Kang, MD, PhD,a,* Bruna Leal Assuncao, MD,b,* Srinivas Denduluri, PhD,a Shannon McCurdy, MD,c Selina Luger, MD,c Bénédicte Lefebvre, MD,a Joseph Carver, MD,a,d Marielle Scherrer-Crosbie, MD, PhDa

ABSTRACT

OBJECTIVES The purpose of this study was to investigate the occurrence and develop a risk score for heart failure (HF) in acute leukemia.

BACKGROUND Knowledge is scarce regarding the incidence and risk factors of symptomatic HF in patients with acute leukemia.

METHODS Baseline clinical and echocardiographic parameters, including indices of cardiac function (left ventricular ejection fraction and myocardial strain [global longitudinal strain; GLS]), were obtained in 450 patients with acute leukemia treated with anthracyclines, before chemotherapy initiation. Potential risk factors for HF were evaluated using Fine and Gray’s regression analysis, and from this, a 21-point risk score was generated.

RESULTS Forty patients (8.9%) developed HF. The HF risk score included a baseline GLS >15% (indicative of greater impairment) (6 points), baseline left ventricular ejection fraction <50%, pre-existing cardiovascular disease, acute myeloid leukemia (4 points each), cumulative anthracycline dose ≥250 mg/m² (2 points), and age >60 years (1 point). Patients were stratified into low (score 0 to 6), moderate (score 7 to 13), and high risk (score 14 to 21). The estimated 1-year cumulative incidence of HF for low-, moderate-, and high-risk groups was 1.0%, 13.6%, and 35.0%, respectively (p < 0.001). The HF risk score was also predictive of all-cause mortality (p < 0.001). After adjustment for age and leukemia type, however, only GLS was significantly associated with all-cause mortality (hazard ratio: 1.73; 95% confidence interval: 1.30 to 2.31; p < 0.001).

CONCLUSIONS We developed a baseline risk score to determine risk of HF in patients with acute leukemia. Additional studies are needed to determine the external validity of these findings. (J Am Coll Cardiol CardioOnc 2019;1:208–17) © 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Over the past decade, the incidence of acute leukemia has been increasing, approximately 0.5% per year from 2004 and 2007 for both sexes, and by 1.6% per year in men and 0.6% per year in women from 2007 to 2011. An estimated 25,480 new cases of acute leukemia will be diagnosed in the United States in 2018 (1,2). In parallel, leukemia-directed therapy has improved, leading to a significant increase in the overall survival of patients with leukemia. The incidence of death has declined by 0.8% in male and 1.4% in female patients from 2004 to 2007, and approximately 1.0% per year in both sexes from 2006 to 2015 (1,2). Improved survival, however, unmasks the impact of comorbidities. Heart failure (HF), compounded by the use of cardiotoxic cancer therapy, is now a leading cause of death and disability among cancer survivors (3,4). For example, HF as a result of anthracycline therapy has been linked to a 3.5-fold increased mortality risk compared with idiopathic cardiomyopathy.

**METHODS**

This study was conducted at the Hospital of the University of Pennsylvania (HUP). HUP maintains an integrated medical record system of all encounters that identifies each patient with a unique number, which served as the basis for our analysis. This unique number was also used in other hospitals or outpatient clinics within the University of Pennsylvania Health System. The institutional review board of the University of Pennsylvania approved the study.

**IDENTIFICATION OF PATIENTS AND ENDPOINTS.** All consecutive adult patients (≥18 years of age) with newly diagnosed AML or ALL treated with anthracyclines at HUP between January 2004 and April 2018 were identified. Patients without available baseline echocardiographic images or with poor echocardiographic image quality (defined as >2 nonvisualized segments) or lack of follow-up record after the first hospital admission were excluded. We accessed each individual’s medical record from HUP and other hospitals or outpatient clinics within the entire University of Pennsylvania Health System. Patients were monitored based on a recommended protocol (15), that included quarterly visits throughout the first to third year and biannual visits; thereafter, ensuring that events of interest could be successfully captured. If patients had no encounters over the preceding 12 months before the end of the study (June 30, 2018), there was a search for published obituaries. Incomplete follow-up was defined as no encounters within 12 months of the end of the study (June 30, 2018) and no notice of death.

We defined symptomatic HF based on the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials (15). Symptomatic HF was confirmed if the patients had at least 1 of the new-onset or worsening HF symptoms (dyspnea, decreased exercise tolerance, fatigue, other symptoms of worsened end-organ perfusion or volume overload) as well as 1 of the following criteria: 1) at least 2 physical examination findings (peripheral edema, increasing abdominal distension or ascites in the absence of primary hepatic disease, pulmonary rales/crackles/crepitations, increased jugular venous pressure and/or hepatojugular reflux, S3 gallop, significant/rapid weight gain related to fluid retention) or 1 physical examination finding and at least 1 piece of laboratory evidence supporting the diagnosis (increased B-type natriuretic peptide/N-terminal...
pro-B-type natriuretic peptide; radiological evidence of pulmonary congestion; noninvasive evidence of elevated left- or right-sided ventricular filling pressure or low cardiac output; invasive diagnostic evidence of elevated pulmonary capillary wedge pressure, central venous pressure, or low cardiac index; and 2) at least 1 relevant HF therapy, whether pharmacological, mechanical, or both. Symptomatic HF was adjudicated by 2 independent cardiologists (YK and BL). A decrease in LVEF secondary to sepsis was not adjudicated as HF. Disagreement between the 2 readers was adjudicated by a third cardiologist (MSC).

Pre-existing cardiovascular (CV) risk factors and CV diseases were extracted electronically from the chart using the relevant International Classification of Diseases-9th and/or 10th Revision-Clinical Modification (ICD-9 and/or ICD-10) codes. Pre-existing CV diseases were defined as coronary artery disease, chronic HF, atrial fibrillation, and stroke/transient ischemic attack. Cardiovascular risk factors included obesity, hypertension, hypercholesterolemia, and diabetes. The confirmation of all the pre-existing diseases or risk factors required the presence of diagnostic codes (ICD-9 and/or ICD-10) as well as either relevant pharmacological therapies or objective findings or signs, including laboratory evidence supporting the diagnosis. Each chart was reviewed individually to determine HF occurrence, pre-existing CV disease, or CV risk factors. Anthracycline dose was calculated based on the following doxorubicin hematologic toxicity equivalence: daunorubicin, 1.0; idarubicin, 5.0; epirubicin, 0.67; and mitoxantrone, 4.0 (16). Noncardiac death was also noted. Death due to septic shock, multiple organ failure, or death after being transferred to hospice was counted as a noncardiac death.

ECHOCARDIOGRAPHY AND STRAIN ANALYSIS. Prechemotherapy echocardiographic images (within 3 months preceding the diagnosis of acute leukemia) were extracted from a hospital-wide echocardiographic database. LVEF was calculated using the modified Simpson’s biplane method. Other echocardiographic parameters of cardiac size and function were measured according to the recommendations of the American Society of Echocardiography (17). Endocardial longitudinal strain was quantified by an offline vendor-independent analysis program (2D Cardiac Performance Analysis; TomTec Imaging Systems, Munich, Germany) at a frame rate of 30 frames per second. The endocardial borders were traced from the 3 apical views by an observer blinded to the clinical characteristics. Global longitudinal strain (GLS) was calculated by measuring the entire endocardial line length at the end-diastole and end-systole in each view and averaging the results from the 3 views (18). Each measurement was taken from the average of 3 consecutive cardiac cycles. Intra- and interobserver variability of LVEF and GLS were assessed by calculating the difference between the values of 10 randomly selected patients measured by 1 observer twice (intra) and by a second observer (inter).

STATISTICAL ANALYSIS, RISK SCORE MODEL DEVELOPMENT, AND VALIDATION. Values are expressed as mean ± SD or counts (percentages). Follow-up time is presented as median (25th and 75th percentile). Differences between patients with AML or ALL or between patients included or excluded in the study were determined using one-way analysis of variance or Kruskal-Wallis test. Categorical variables were compared using the chi-square test. Intraobserver and interobserver reproducibility of LVEF and GLS was assessed using the intraclass correlation coefficients (ICCs). Time-on-study was used as time scale in all survival analyses. Follow-up began at the start of anthracyclines and ended in case of death, event of interest, or the date of last encounter (before June 30, 2018), whichever came first. The cumulative incidence function was used to estimate the incidence of HF, with noncardiac death as a competing event. Univariable Cox proportional hazard regression models were used to analyze the association between baseline variables and HF. Time-dependent covariates were used to assess the presence of nonproportional
hazards by including interactions of each covariates with a function of time (19). Because of competing risks, univariable Fine and Gray’s subdistribution hazard regression models were also used to determine the association between clinical parameters and HF. The results of Cox proportional hazard models and Fine-Gray subdistribution hazard models were presented as hazard ratios (HRs) with 95% confidence interval (CI).

We developed a multivariable Fine and Gray’s subdistribution hazard regression model through the inclusion of variables with a p < 0.10 in univariable analysis, and according to their hypothesized clinical relevance to avoid colinearity. For continuous variables, the variables were categorized using recognized clinical meaningful categories, as follows: age: <40 years of age, 40 to 60 years of age, and >60 years of age; cumulative dose of anthracyclines: <250 mg/m², ≥250 mg/m²; LVEF: <50% and ≥50%; and GLS: >−15% (more impaired) and ≤−15% (20,21).

To develop the risk score, we used a stepwise forward approach to establish the multivariable regression model and selected the best model by calculating the time-dependent area under the receiver operating characteristics curve (AUC) and Bayesian information criteria (BIC) for each regression model (22,23). Model performance was further evaluated using Brier scores by 10-fold cross-validation method (23). Risk points were assigned to the variable proportional to their regression coefficient (24). The sum of all points was calculated for each patient. The patients were then divided into subgroups on the basis of the score. The cumulative incidence of HF for the subgroups were used to define 3 groups: high, moderate, and low risk for HF (24). Cumulative incidence function curves for patients in the 3 risk groups were generated to illustrate the partitioning of the risk of symptomatic HF, and Fine and Gray’s method was used to determine if there were significant differences between groups.
In exploratory analyses, we also evaluated the relationship between the risk model and the outcome of all-cause death. Here, the association of each variable in the risk score with mortality was also tested using the Cox proportional hazard model. Kaplan-Meier survival curves for different GLS values were also generated for this outcome.

Data were analyzed by SPSS version 16.0 (SPSS, Chicago, Illinois) and R version ii386 3.5.0 (Vienna, Austria). A p < 0.05 was considered statistically significant.

RESULTS

PATIENT ENROLLMENT. A total of 645 patients with AML or ALL were treated with anthracyclines at HUP from January 2004 to April 2018. After excluding patients without an echocardiogram before the initiation of anthracycline treatment, lack of follow-up after baseline visit (as defined by lack of follow-up record after the first hospital admission), and poor echocardiographic image quality, a total of 450 patients (218 men, ranging in age from 18 to 83 years) were included in the study cohort (median follow-up period: 16 months; range: 1 to 132 months; first to third quartiles: 10 to 32 months) (Figure 1). Baseline clinical characteristics were similar between the included and excluded patients, with the exception of sex (Supplemental Table 1). Nine patients (2.0%) had incomplete follow-up (age: 38 ± 13 years, ranging from 22 to 55 years; median follow-up time: 70 months, ranging from 60 to 96 months; mean

(A) Cumulative incidence curves of symptomatic heart failure (HF) and noncardiac death in all patients. (B) Cumulative incidence curves of HF were plotted according to risk score groups. (C) Kaplan-Meier survival curves of all-cause death according to risk score groups. (D) Kaplan-Meier survival curves for all-cause death in patients with GLS above or below –15%. GLS = global longitudinal strain.
cumulative dose of anthracyclines: $263 \pm 98 \text{ mg/m}^2$, ranging from 140 to 450 mg/m$^2$.

Forty patients (8.9%) developed symptomatic HF, including 1 patient with decompensated HF who subsequently died (Central Illustration). The median time to develop HF was 10 months (range, 1 to 76 months; interquartile range: 5 to 32 months); 215 patients (47.8%) died of a noncardiac cause. The cumulative incidence of HF and noncardiac death are shown in Figure 2A.

**CLINICAL CHARACTERISTICS OF ENROLLED PATIENTS.** The baseline clinical characteristics of the enrolled patients are presented in Table 1. Patients who developed HF were older, with a higher prevalence of previous HF, atrial fibrillation, and pre-existing CV diseases.

**BASELINE ECHOCARDIOGRAPHIC CHARACTERISTICS OF PATIENTS.** Baseline echocardiographic findings are listed in Table 2. The overall baseline LVEF was 63 ± 8%. Patients with HF had larger indexed left ventricular end-diastolic volume and left ventricular end-systolic volumes with lower LVEF, compared with patients with noncardiac death and patients with no events. Baseline GLS values were worse (more impaired) in patients who developed HF, compared with patients with noncardiac death and patients with no events (−13.0 ± −3.6%, −17.2 ± −3.2%, and −18.4 ± −2.6%, respectively).

**RELIABILITY OF GLS AND LVEF ANALYSIS.** The ICC was 0.92 for LVEF and 0.91 for GLS for the intra-observer variability. The ICC was 0.88 for LVEF and 0.89 for GLS for interobserver variability.

**DEVELOPMENT OF A RISK SCORE.** Baseline clinical and echocardiographic parameters associated with HF by univariable Cox proportional hazard analysis and by Fine and Gray’s subdistribution hazard analysis are presented in Supplemental Table 2.

Covariates with a $p < 0.10$ in univariable analyses were older than 60 years, previous HF, atrial fibrillation, pre-existing CV diseases, prescribed angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, presence of AML, cumulative dosage of anthracyclines $\geq 250 \text{ mg/m}^2$, baseline left ventricular end-systolic dimension, left ventricular end-diastolic volume, left ventricular end-systolic volume, left ventricular mass index, LVEF <50%, and GLS $>−15$% (indicative of greater impairment) in both Cox proportional hazard analysis and Fine and Gray’s subdistribution proportional hazard analysis. To avoid colinearity, we chose pre-existing CV disease rather than previous HF or atrial fibrillation, and baseline LVEF <50% and baseline GLS rather than other echocardiographic parameters. We included age and cumulative anthracycline dose as clinically relevant variables. Thus, 6 variables (age $>60$ years, cumulative anthracycline dose $\geq 250 \text{ mg/m}^2$, presence of AML, pre-existing CV disease, baseline LVEF <50%, and baseline GLS $>−15$%) were selected based on their statistical significance and clinical relevance. We tested combinations of these variables. Adding GLS in the model with clinical characteristics increased AUC, providing incremental value (Supplemental Figure 1B). We chose these parameters to establish the risk score.

The Brier scores were calculated to test the predictive accuracy of the model (Supplemental Figure 1B). We

---

**TABLE 1 Baseline Clinical Characteristics of the Study Cohort**

| Cohort (N = 450) | No Events (n = 195) | Noncardiac Death (n = 215) | HF (n = 40) |
|------------------|---------------------|----------------------------|-------------|
| **Demographics** |                     |                            |             |
| Age, yrs         | 51 ± 15             | 46 ± 15                    | 55 ± 15     |
| Male             | 218 (48)            | 89 (46)                    | 107 (50)    |
| BMI, kg/m$^2$    | 27.5 ± 5.7          | 27.6 ± 5.7                 | 27.6 ± 5.8  |
| **Cardiovascular disease history** | | | |
| Hypercholesterolemia | 97 (22)            | 47 (24)                    | 42 (20)     |
| Hypertension     | 163 (36)            | 69 (35)                    | 80 (37)     |
| Diabetes         | 36 (8)              | 17 (9)                     | 17 (8)      |
| Current/previous smoker | 182 (40)          | 61 (31)                    | 103 (48)    |
| $\geq 2$ CV risk factors* | 117 (39)          | 54 (28)                    | 54 (25)     |
| Congestive HF    | 11 (2)              | 0 (0)                      | 2 (1)       |
| Coronary heart disease | 27 (6)           | 8 (4)                      | 15 (7)      |
| Atrial fibrillation | 34 (8)              | 6 (3)                      | 18 (8)      |
| Peripheral artery disease | 8 (2)            | 2 (1)                      | 5 (2)       |
| Chronic kidney disease | 12 (3)          | 6 (3)                      | 4 (2)       |
| Pre-existing CV diseases† | 67 (15)        | 13 (7)                     | 33 (15)     |
| **Cardiovascular medication** | | | |
| Beta-blockers    | 85 (19)             | 37 (19)                    | 38 (18)     |
| ACEI/ARBs        | 83 (18)             | 25 (13)                    | 46 (21)     |
| Statins          | 84 (19)             | 42 (22)                    | 33 (15)     |
| **Leukemia type** |                     |                            |             |
| ALL              | 149 (33)            | 90 (60)                    | 54 (36)     |
| AML              | 301 (67)            | 105 (35)                   | 161 (53)    |
| **Oncological history** |                  |                            |             |
| Previous anthracyline exposure | 31 (7)        | 15 (8)                     | 12 (6)      |
| Cumulative anthracyline dose, mg/m$^2$ | 183 ± 86     | 189 ± 94                   | 174 ± 78    |
| BMT/PBSCT        | 204 (45)            | 96 (49)                    | 89 (41)     |

*CV risk factors include obesity, hypertension, hypercholesterolemia and diabetes. †CV diseases include coronary artery disease, chronic heart failure, atrial fibrillation, and stroke/transient ischemic attack.

ACEI = angiotensin-converting enzyme inhibitor; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; ARB = angiotensin II receptor blocker; BMI = body mass index; BMT = bone marrow transplantation; CV = cardiovascular; HF = heart failure; PBSCT = peripheral blood stem cell transplantation.

Values are means ± SD or n (%). *CV risk factors include obesity, hypertension, hypercholesterolemia and diabetes. †CV diseases include coronary artery disease, chronic heart failure, atrial fibrillation, and stroke/transient ischemic attack.
TABLE 2 Baseline Echocardiographic Parameters of the Study Cohort

| Variable                  | Cohort (N = 450) | No Events (n = 195) | Noncardiac Death (n = 215) | HF (n = 40) |
|---------------------------|------------------|---------------------|---------------------------|-------------|
| LVEDD, mm                 | 46 ± 6           | 46 ± 7              | 46 ± 5                    | 48 ± 9      |
| LVESD, mm                 | 31 ± 6           | 30 ± 5              | 31 ± 5                    | 35 ± 7      |
| LVEDVI, ml/m²             | 53.0 ± 15.0      | 53.0 ± 14.4         | 51.8 ± 13.3               | 59.7 ± 23.1 |
| LVESVI, ml/m²             | 19.7 ± 8.1       | 18.8 ± 6.5          | 18.9 ± 6.4                | 28.1 ± 15.3 |
| RWT                       | 0.44 ± 0.21      | 0.44 ± 0.24         | 0.44 ± 0.10               | 0.41 ± 0.10 |
| LV mass index, g/m²       | 83.5 ± 23.2      | 79.1 ± 21.8         | 85.3 ± 22.5               | 95.4 ± 27.9 |
| LVEF, %                   | 63 ± 8           | 65 ± 6              | 64 ± 7                    | 55 ± 11     |
| LVEF <53%                 | 30 (7)           | 4 (2)               | 8 (4)                     | 18 (45)     |
| DT, ms                    | 181 ± 55         | 181 ± 51            | 184 ± 58                  | 173 ± 62    |
| E/E’                      | 7.8 ± 3.5        | 7.3 ± 2.5           | 8.2 ± 4.2                 | 8.6 ± 3.2   |
| GLS, %                    | −17.3 ± 3.3      | −18.4 ± 2.6         | −17.2 ± 3.2               | −13.0 ± 3.6 |
| GLS >−15%                 | 84 (19)          | 13 (7)              | 44 (20)                   | 27 (68)     |

Values are mean ± SD or n (%).

DT = deceleration time; E/E’ = ratio between early mitral inflow velocity (E) measured by pulsed-wave Doppler and mitral annular early diastolic velocity (E’) estimated by tissue Doppler; GLS = global longitudinal strain; LV = heart failure; LVEDD = left ventricular end-diastolic dimension; LVEDVI = indexed left ventricular diastolic volume; LVESV = left ventricular end-systolic volume; RWT = relative wall thickness.

TABLE 3 Variables Included in Multivariable Fine and Gray’s Subdistribution Hazard Regression Model

| Variable                              | HR (95% CI) | β Coefficient Value | p Value | Score Points |
|---------------------------------------|-------------|---------------------|---------|-------------|
| GLS >−15%                             | 6.91 (3.27–14.59) | 1.93 | <0.001 | 6          |
| Pre-existing CV disease                | 3.74 (1.82–7.67) | 1.32 | <0.001 | 4          |
| Leukemia type (AML)                   | 4.10 (1.90–8.85) | 1.41 | <0.001 | 4          |
| EF <50%                               | 3.50 (1.64–7.51) | 1.25 | <0.001 | 4          |
| Age >60 yrs                            | 1.36 (0.76–2.44) | 0.31 | 0.300 | 1          |
| Anthracycline dose ≥250 mg/m²          | 1.96 (1.06–3.61) | 0.67 | 0.030 | 2          |

CI = confidence interval; CV = cardiovascular; EF = ejection fraction; GLS = global longitudinal strain; HR = hazard ratio.

The present study demonstrates that patients with AML and ALL treated with anthracyclines are at risk of HF, most of which occurs within 1 year after the exposure of anthracyclines. We determined that a risk score based on baseline clinical and echocardiographic variables can stratify patients at low or high risk for HF after treatment for acute leukemia.

The population studied consisted of patients with acute leukemia treated with anthracyclines, whose clinical characteristics were similar to those encountered in everyday clinical practice, in terms of the incidence of HF for the low-, moderate-, and high-risk groups was 0.8%, 15.8%, and 33.7%, and 1.3%, 11.6%, and 38.8%, respectively.

RISK SCORE IN PATIENTS WITH AML OR ALL. Patients with AML had a higher incidence of HF and noncardiac mortality than patients with ALL (11.6% vs. 3.4%, 52.8% vs. 34.9%, respectively; p < 0.001 for both). The baseline characteristics of patients with either AML or ALL are shown in Supplemental Table 3.

Patients with AML were older and received higher doses of anthracyclines; however, after adjustment for age and cumulative anthracycline dose, the presence of AML was still associated with symptomatic HF (HR: 2.77; 95% CI: 1.01 to 7.63; p = 0.048).

We further tested a modified risk score in patients with ALL separately. After excluding presence of AML, the modified risk score, that is, a 17-point score including a baseline GLS >−15% (6 points), pre-existing CV disease (4 points), baseline LVEF <50% (4 points), a cumulative dose of anthracycline ≥250 mg/m² (2 points), and age >60 years (1 point) stratified patients with ALL (n = 149) into low (score 0 to 1, n = 103), moderate (score 2 to 10, n = 40), and high risk (score 11 and above, n = 4). The 1-year estimated cumulative incidence of symptomatic HF of low-, moderate-, and high-risk groups in patients with ALL was <0.1%, 3.6%, and 17.0%, respectively (p < 0.001).

RELATIONSHIP OF THE RISK SCORE, GLS, AND OVERALL MORTALITY. In exploratory analyses, the risk score was also associated with all-cause death (HR: 1.36; 95% CI: 1.23 to 1.50; p < 0.001). The overall survival time was significantly greater in patients in low-risk score group than those in moderate- and high-risk groups (p < 0.001) (Figure 2C). After adjustment for age and leukemia type, only GLS >−15% remained independently related to all-cause death (HR: 1.73; 95% CI: 1.30 to 2.31; p < 0.001) (Figure 2D). The presence of pre-existing CV disease and baseline LVEF <50% were not independently associated with overall mortality.

DISCUSSION

The present study demonstrates that patients with AML and ALL treated with anthracyclines are at risk of HF, most of which occurs within 1 year after the exposure of anthracyclines. We determined that a risk score based on baseline clinical and echocardiographic variables can stratify patients at low or high risk for HF after treatment for acute leukemia.

The population studied consisted of patients with acute leukemia treated with anthracyclines, whose clinical characteristics were similar to those encountered in everyday clinical practice, in terms of the
In exploratory analyses, the risk score also was associated with overall mortality (1,2); however, when adjusted for age and leukemia type, only reduced GLS in baseline echocardiography was independently associated with all-cause death. A high production of proinflammatory cytokines, in particular tumor necrosis factor-α and interleukin-6 (30,31), is associated with a poor prognosis in patients with cancer (40). High levels of proinflammatory cytokines also exert cardio-depressant effects that lead to decreased myocardial contractility and left ventricular performance (41). Thus, GLS may be an indicator of disease burden in patients with cancer. In addition, patients with reduced left ventricular function might not receive as aggressive a cancer treatment as patients with normal cardiac function.

**STUDY LIMITATIONS.** This risk score was developed in a single, tertiary care center. Although the cohort was representative of patients with acute leukemia, the risk score has not been validated prospectively or validated externally in a separate cohort. Second, selection bias might have occurred, because we excluded patients with a lack of follow-up. However, the baseline characteristics between patients who were included and excluded showed no substantial differences. A large-scale prospective validation across multiple distinct medical centers would substantially strengthen this risk score. Without a comparator group, we could not further investigate whether the use of anthracyclines, or various anthracycline treatment schedules, had an effect on the occurrence of HF. We did, however, find that a cumulative dose of anthracyclines $\geq$250 mg/m$^2$ was a risk factor for HF.

**CONCLUSIONS**

We developed a risk score based on 4 readily acquired baseline clinical and echocardiographic variables to stratify patients according to a low or high risk of symptomatic HF. With further study, a scoring system may be useful to clinicians to balance the benefits of cancer treatment and potential cardiac damage.

**ACKNOWLEDGMENTS** The authors thank Jesse Chittams MS, and Ronald Kamusiime, MS, for the statistical analysis help.

**ADDRESS FOR CORRESPONDENCE:** Dr. Marielle Scherrer-Crosbie, Division of Cardiovascular Diseases, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA. E-mail: Marielle.Scherrer-Crosbie@pennmedicine.upenn.edu. Twitter: @mariellesc1.
Heart Failure in Patients With Acute Leukemia

COMPETENCY IN MEDICAL KNOWLEDGE AND IN PATIENT CARE: Patients with acute myeloid leukemia and acute lymphocytic leukemia treated with anthracyclines are at risk of symptomatic heart failure, most of which occurs within 1 year after exposure to anthracyclines. A risk score based on baseline clinical and echocardiographic variables can be used to classify patients as low or high risk for heart failure after anthracyclines.

TRANSLATIONAL OUTLOOK: Baseline clinical and echocardiographic parameters are associated with symptomatic heart failure in patients with acute leukemia. Additional studies are needed to further validate the score, and determine both the efficacy and effectiveness of such a risk score in clinical practice.

REFERENCES
1. American Cancer Society. Cancer Facts & Figures. 2015. Available at: https://www.cancer.org/research/cancer-facts-statistics.html. Accessed June 30, 2018.
2. American Cancer Society. Cancer Facts & Figures. 2012. Available at: https://www.cancer.org/research/cancer-facts-statistics.html. Accessed June 30, 2018.
3. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association. Eur J Heart Fail 2013;15:1064.
4. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011;13:R64.
5. Hoezler D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C, on behalf of the ESMO guidelines committee. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2006;17 Suppl 5:v69-82.
6. Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia. Version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019;17:721-49.
7. Wang L, Tan TC, Halpern EF, et al. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. Am J Cardiol 2015;116:442-6.
8. Kang Y, Cheng L, Li L, et al. Early detection of anthracycline-induced cardiotoxicity using two-dimensional speckle tracking echocardiography. Cardiol J 2013;20:592-9.
9. Kang Y, Wang W, Zhao H, Qiao Z, Shen X, He B. Assessment of subclinical doxorubicin-induced cardiotoxicity in a rat model by speckle-tracking imaging. Arq Bras Cardiol 2017;109:132-9.
10. Kang Y, Xiao F, Chen H, et al. Subclinical anthracycline-induced cardiotoxicity in the long-term follow-up of lymphoma survivors: a multi-layer speckle tracking analysis. Arq Bras Cardiol 2018;110:219-28.
11. Song F, Kang Y, Zhang C, et al. The early variation of left ventricular twisting function in patients with lymphoma received anthracycline therapy assessed by three-dimensional speckle tracking echocardiography. Cardiol J 2017;24:484-94.
12. Kang Y, Xu, Cheng L, et al. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicin-based chemotherapy. Eur J Heart Fail 2014;16:300-8.
13. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596-603.
14. Bergler-Klein J. Strain and left ventricular volumes for predicting cardiotoxicity: a life-saving approach in anthracycline cancer treatment. Eur Heart J Cardiovasc Imaging 2015;16:968-9.
15. Hicks KA, Mahaffey KW, Mehran R, et al., Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation 2018;137:961-72.
16. Aboussoud I, Greenberg ML, Ness KK, Benson L, Nathan PC. Echocardiographic surveillance for asymptomatic late onset anthracycline cardiomyopathy in childhood cancer survivors. Pediatr Blood Cancer 2011;57:467-72.
17. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.
18. Voigt JU, Pedridzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr 2015;28:183-93.
19. Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in Cox regression models. Ann Transl Med 2018;6:121.
20. Stampehi MR, Mann DL, Nguyen JS, Kota F, Colmenares C, Dokainish H. Speckle strain echocardiography predicts outcome in patients with heart failure with both depressed and preserved left ventricular ejection fraction. Echocardiography 2015;32:71-8.
21. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al., Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 2017;19:9-42.
22. Seruca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010;45:1388-95.
23. Zhang A, Cortese G, Combesucre C, et al. Overview of model validation for survival regression model with competing risks using melanoma study data. Ann Transl Med 2018;6:325-33.
24. Austin PC, Lee DS, D’Agostino RB, Fine JP. Developing points-based risk-scoring systems in the presence of competing risks. Stat Med 2016;35:4056-72.
25. Shah A, Andersson TM, Rachet B, Björkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England 1971-2006: a population-based study. Br J Haematol 2013;162:509-16.
26. Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD. Based on November 2017 SEER data submission, posted to the SEER Web site, April 2018. Available at: https://seer.cancer.gov/csr/1975_2015/. Accessed November 2019.
27. Fryar CD, Chen TC, Li X. Prevalence of uncontrolled risk factors for cardiovascular disease. United States, 1999-2010. NCHS Data Brief 2012;103:1-8.
28. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1976;91:710-7.
29. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003;97:2869-79.
30. Sanchez-Correa B, Bergua JM, Campos C, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine 2013;61:885-91.
31. Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008;113:1606-13.
32. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:2488-98.
33. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017;377:111-21.
34. Ho PA, Alonzo TA, Kopecky KJ, et al. Molecular alterations of the idh1 gene in aml: a Children’s Oncology Group and Southwest Oncology Group study. Leukemia 2010;24:909-13.
35. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010;115:2749-54.
36. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated idh1 and idh2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-34.
37. Karlstaedt A, Zhang X, Vitrac H, et al. Oncometabolite D-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc Natl Acad Sci U S A 2016;113:10436-41.
38. Wang F, Travins J, Lin Z, et al. A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model. J Inherit Metab Dis 2016;39:807-20.
39. Ali MT, Yucel E, Bouras S, et al. Myocardial strain is associated with adverse clinical cardiac events in patients treated with anthracyclines. J Am Soc Echocardiogr 2016;29:522-7.
40. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011;104:726-34.
41. Kalogeropoulos AP, Georgiopoulou VV, Butler J. From risk factors to structural heart disease: the role of inflammation. Heart Fail Clin 2012;8:113-23.

**KEY WORDS** acute leukemia, anthracycline, cardiotoxicity, global longitudinal strain, heart failure, risk score

**APPENDIX** For supplemental tables and a figure, please see the online version of this paper.